Otsuka Pharmaceutical Development & Commercialization, Inc.
otsuka-us.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
284
Active
15
Phase 3
137
Total enrollment
161,583
Pipeline matrix
Showing 22 of 22 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| JNT-517 | — | — | — | — | 4 | ||
| Tolvaptan | — | — | — | — | 22 | ||
| SEP-363856 | — | — | — | 18 | |||
| Sibeprenlimab 400 mg | — | — | — | — | — | 1 | |
| Sibeprenlimab 400 mg s.c. Q4weeks | — | — | — | — | — | 1 | |
| Tolvaptan Suspension | — | — | — | — | — | 1 | |
| BPaQM | — | — | — | — | — | 1 | |
| BPaLM | — | — | — | — | — | 1 | |
| BPaQ | — | — | — | — | — | 1 | |
| BPaL | — | — | — | — | — | 1 | |
| Sibeprenlimab | — | — | — | — | — | 2 | |
| Metformin | — | — | — | — | — | 2 | |
| Carbamazepine | — | — | — | — | — | 2 | |
| VIS171 | — | — | — | — | — | 2 | |
| Repinatrabit | — | — | — | — | — | 1 | |
| EE/NE | — | — | — | — | — | 1 | |
| Rosuvastatin | — | — | — | — | — | 1 | |
| Methotrexate | — | — | — | — | — | 1 | |
| 14C-SEP-380135 | — | — | — | — | — | 1 | |
| NDI-5001 | — | — | — | — | — | 1 | |
| HBM7020 | — | — | — | — | — | 1 | |
| MSP-2020 | — | — | — | — | — | 1 |
Next readouts
- 2026-04-10
- 2026-05-13
- 2026-06-09
- 2026-10-20
- 2026-12-01
- 2027-01-29
- 2027-03-13
- 2027-04-14
- 2027-05-28
- 2027-11-01
Top conditions
- Schizophrenia82
- Major Depressive Disorder16
- Bipolar Disorder14
- Bipolar I Disorder12
- Depressive Disorder, Major9
- Healthy Volunteers8
- Mental Disorder8
- Major Depressive Disorder (MDD)7
Frequently asked questions about Otsuka Pharmaceutical Development & Commercialization, Inc.
- How many clinical trials does Otsuka Pharmaceutical Development & Commercialization, Inc. have on ClinicalTrials.gov?
- Otsuka Pharmaceutical Development & Commercialization, Inc. is listed as the lead sponsor on 284 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Otsuka Pharmaceutical Development & Commercialization, Inc.'s trials are in Phase 3?
- 137 of Otsuka Pharmaceutical Development & Commercialization, Inc.'s trials are in Phase 3, spread across 22 active drug programs.
- What therapeutic areas does Otsuka Pharmaceutical Development & Commercialization, Inc. focus on?
- Otsuka Pharmaceutical Development & Commercialization, Inc.'s most-studied conditions on ClinicalTrials.gov are Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Bipolar I Disorder, Depressive Disorder, Major.
- When are Otsuka Pharmaceutical Development & Commercialization, Inc.'s next clinical trial readouts?
- Otsuka Pharmaceutical Development & Commercialization, Inc. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults”, expected around 2026-04-10.